Identifying and Targeting the Molecular Signature of Smooth Muscle Cells Undergoing Early Vascular Aging

Early vascular aging (EVA) is distinct from chronological ageing, and research is ongoing to identify a definitive molecular signature of EVA. This will facilitate the discovery of new clinical tests for early detection of EVA and identify therapeutic targets to halt (or prevent) EVA in smooth muscle cells, thus reducing macrovascular morbidity and mortality.